Bardsley G, et al. - In this single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study, researchers determined the time-course of onset and offset of airway anti-inflammatory action of fluticasone furoate/vilanterol trifenatate (FF/VI), as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action. Study participants included 28 steroid-naïve adults with asthma with an forced expiratory volume in one second (FEV₁) ≥ 60% predicted, reversible airway disease, and FeNO > 40 ppb. These subjects were administered FF/VI 100/25 mcg or placebo once daily for 14 days. They found that anti-inflammatory duration of action of FF/VI was consistent with the high glucocorticoid receptor affinity and long lung retention of fluticasone furoate. FF/VI had greater duration of anti-inflammatory effect relative to its bronchodilator effect in adults with mild asthma.